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Dapsone hypersensitivity syndrome causing disseminated intravascular 
coagulation 
Abstract 
Dapsone hypersensitivity syndrome is an idiosyncratic reaction to this drug and can present with different 
clinical manifestations of varying severity. We describe a patient with disseminated intravascular 
coagulation (DIC) as an adverse reaction to dapsone. To the best of our knowledge, this is the first time it 
has been described in the literature. She presented with fever, rash and abdominal pain; she also had 
marked eosinophilia and features suggestive of oxidative haemolysis. Her course was complicated by 
DIC, splenic infarction and gastrointestinal bleeding. Extensive investigations did not reveal any 
alternative aetiology. She was initially treated with supportive measures and folic acid; steroids were 
administered later, following clinical deterioration. There was gradual improvement and the steroids were 
tapered. The patient recovered fully and remains well; her underlying chronic dermatologic condition is 
under satisfactory control with other medications. 
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Unexpected outcome (positive or negative) including adverse 
drug reactions 
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SUMMARY 
Dapsone hypersensitivity syndrome is an idiosyncratic reaction to this drug and can present with 
different clinical manifestations of varying severity. We describe a patient with disseminated 
intravascular coagulation (DIC) as an adverse reaction to dapsone. To the best of our knowledge, this is 
the first time it has been described in the literature. She presented with fever, rash and abdominal pain; 
she also had marked eosinophilia and features suggestive of oxidative haemolysis. Her course was 
complicated by DIC, splenic infarction and gastrointestinal bleeding. Extensive investigations did not 
reveal any alternative aetiology. She was initially treated with supportive measures and folic acid; 
steroids were administered later, following clinical deterioration. There was gradual improvement and 
the steroids were tapered. The patient recovered fully and remains well; her underlying chronic 
dermatologic condition is under satisfactory control with other medications.  
 
BACKGROUND 
This case illustrates the challenges a clinician may face with life threatening adverse reactions from a 
medication used commonly in various parts of the world, for a variety of indications by doctors of several 
specialties, as well as general physicians and family practitioners.  
CASE PRESENTATION 
A 44-year-old Chinese woman presented with a 6 day history of fatigue, fever, pruritic rash, nausea and 
abdominal pain. Three weeks earlier she was prescribed dapsone 100 mg daily for dermatitis 
herpetiformis, which she stopped taking 2 days before admission. Her personal medical and family 
history was unremarkable. Examination revealed temperature 40°C, blood pressure 90/50 mm Hg, 
bilateral pleural effusions, scleral icterus, tender upper quadrants bilaterally and inguinal 
lymphadenopathy. There was a diffuse non-blanching maculopapular exanthem over the abdomen, 
arms and legs with sparing of the mucosal areas (fig 1A).  
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Figure 1 (A) Exanthem of dapsone hypersensitivity reaction on abdomen. (B) Peripheral blood film 
showing oxidative haemolysis. (C) Computed tomographic scan of the abdomen showing splenic 
infarction, bilateral pleural effusions and body wall oedema.  
   
INVESTIGATIONS 
Laboratory testing showed oxidative haemolysis (fig 1B) (bilirubin 105 µmol/l, lactate dehydrogenase 
(LDH) 506 IU/l, reticulocytes 269.2x109); neutropenia 0.5x109/l; eosinophilia 1.97x109/l (normal range 
0.04–0.44x109/l); and elevated alanine aminotransferase (ALT) 432 U/l (normal <45 U/l) and aspartate 
transaminase (AST) 129 U/l (normal <45 U/l). Skin biopsy showed moderate interface dermatitis with 
negative IgA/G immunofluorescence. The patient had disseminated intravascular coagulation (DIC) with 
concurrent splenic infarction (fig 1C), gastrointestinal bleeding and abdominal wall haemorrhage; 
international normalised ratio (INR) was 1.6, fibrinogen 1.0 g/l, D-dimers >20 µg/ml, and platelets 
112x109/l. Glucose-6-phosphate dehydrogenase (G6PD) value was normal.  
DIFFERENTIAL DIAGNOSIS 
Thrombotic, septic, vasculitic, and porphyrin screen were negative.  
TREATMENT 
The patient was managed initially with supportive measures and folic acid. Blood products were not 
required. Intravenous steroids were introduced on day 5 in response to rising eosinophilia and worsening 
symptoms. There was marked improvement in temperature and exanthem within 48 hours. The 
eosinophil count fell to 0.24x109/l.  
OUTCOME AND FOLLOW-UP 
Oral steroids were tapered over 4 weeks with resolution of exanthem and normalisation of 
transaminases. Rechallenge was not attempted, in view of the life threatening initial reaction. The 
patient recovered fully and remains well 1 year after her hospitalisation; her underlying chronic 
dermatologic condition is under satisfactory control with other medications. Patient consent was 
obtained for publication of clinical information and additional peripheral blood mononuclear cell (PBMC) 
in vitro tests.  
The effect of dapsone on PBMC proliferation was assessed in vitro with PBMC from the patient and a 
healthy volunteer of same age, sex and ethnic origin. PBMC were Ficoll-isolated and 3x105 PBMC (in 
triplicate) were incubated for 48 h in 100 µl of RPMI-1640 (negative controls) and in the presence of LPS 
(30 µg/ml) (positive control) and dapsone at concentrations of 0.02 µM, 0.2 µM, 2 µM (typical trough 
value in human serum), 20 µM and 200 µM. Proliferation was measured using the methyl thiazolyl 
tetrazolium (MTT) method at 570 nm. Increased proliferation was observed in LPS treated PBMC from 
both patient (35%) and healthy volunteer (44%) compared to PBMC in media only (negative controls), 
whereas dapsone at concentrations 0.02–20 µM had no significant effect. Dapsone at a concentration of 
200 µM had a notable inhibitory effect on cell proliferation in PBMC of both patient (–75%) and control (–
66%).  
DISCUSSION 
Dapsone (4-4'-diaminodiphenylsulphone), a synthetic sulfone, is a potent antimicrobial and anti-
inflammatory drug. Dapsone is used in first line multi-drug treatment of leprosy, for actinomycotic 
mycetoma, and as an alternative agent for prophylaxis against pneumocystosis, toxoplasmosis and 
malaria. Dapsone is an efficacious anti-inflammatory agent in various dermatological conditions 
(dermatitis herpetiformis, acne vulgaris, urticarial vasculitis, and immunobullous diseases).  
Dapsone has well recognised idiosyncratic and predictable adverse effects.1,2 The dapsone 
hypersensitivity syndrome (DHS) is a severe form of DRESS syndrome (drug rash with eosinophilia and 
systemic symptoms). Originally described as a triad of fever, skin eruption and internal organ 
involvement, DRESS syndrome has expanded to include painful lymphadenopathy, eosinophilic 
pulmonary infiltrates and myocarditis. Methaemoglobinaemia and peripheral neuropathy have also been 
described.1 DHS incidence is estimated to be 0.01–3%.3 This idiosyncratic reaction is possibly triggered 
by antibody formation to haptens from dapsone metabolites,4 usually within 8 weeks from starting the 
drug.2 Failure of physiological dapsone concentrations to activate in vitro PBMC proliferation from this 
patient further supports the hypothesis for involvement of dapsone metabolites in DHS. However, the 
possibility of qualitative PBMC alterations in response to dapsone or its metabolites would also be of 
interest.  
DIC has not been previously reported in association with dapsone, despite over 150 cases of DHS 
described in the literature. DIC in this patient may be a consequence of the hypersensitivity reaction 
triggering a severe systemic inflammatory response syndrome (SIRS). Severe inflammation induces 
damaged endothelial and mononuclear cells to express tissue factor which triggers fibrin formation and 
subsequent DIC. In intensive care units, 2% of DIC cases are attributed to inflammatory reactions to 
toxins, recreational drugs, poisons, transfusion reaction or transplant rejection.5 The presence of DIC in 
SIRS has important prognostic implications as coagulation abnormalities perpetuate the inflammatory 
response.  
The mortality among patients with severe DHS is 12–23%.3 The management of DHS is largely 
supportive (fluid and electrolyte balance, haematological, fastidious skin care and prevention of 
secondary infection). Steroid use remains controversial, despite case reports of benefit. Slow steroid 
tapering is recommended as dapsone may persist for up to 35 days as a result of protein binding and 
enterohepatic circulation.1 Thyroid function should be assessed at 3 months, since hypothyroidism due 
to antimicrosomal antibodies is a late complication.  
It is imperative to reduce the likelihood of DHS, by careful assessment of risk factors predisposing the 
patient to this adverse event. Patients at increased risk include those with: sulphone allergy, haemolytic 
anaemia, G6PD deficiency, porphyria, personal or family history of cyanosis, use of concurrent 
medications metabolised by CYP3A4 and CYP2C9, rapid hydroxylators, and slow acetylators.4 
Awareness of the severe, idiosyncratic nature of dapsone reactions warrants careful monitoring of all 





 Therapeutic use of dapsone can be complicated by life threatening idiosyncratic adverse reactions, 
including disseminated intravascular coagulation. 
 Careful consideration needs to be given to whether the patient’s condition warrants dapsone and whether 
the patient is at increased risk of an adverse event. 
 All patients commencing dapsone should be monitored closely, for early recognition of symptoms and 
signs suggesting an adverse drug reaction. 
 The management of adverse effects from dapsone is supportive, involving management of shock, fluid 
and electrolyte balance, pancytopenia, fastidious skin care and prevention of secondary infection. 
Steroids may be used in severe cases not responding to supportive management. 
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